The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock List

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Fri., Feb. 12, 7:17 PM

Slide #15. Baxalta Incorporated Secondary Offering

Company: Baxalta Incorporated (NYSE:BXLT)
Date announced: 1/26/2015
Shares Offered: 37,573,040
Date of Pricing: 1/27/2016
Price Per Share: $39.50
Secondary Offering Details: Baxalta Incorporated (NYSE:BXLT) announced today the commencement of an underwritten public offering of approximately $1.45 billion of its common stock previously issued to and currently owned by Baxter International Inc., Baxalta's former parent company. Baxalta is not selling any shares and will not receive any proceeds from the sale of the shares in the offering or the debt-for-equity exchange (as described below). -updated 1/27- Baxalta Incorporated (NYSE:BXLT) announced today the pricing of its previously announced secondary public offering of 37,573,040 shares of its common stock at a price to the public of $39.50 per share. Baxalta is not selling any shares and will not receive any proceeds from the sale of the shares in the offering or the debt-for-equity exchange (as described below). The offering is expected to close on February 2, 2016, subject to customary closing conditions.

Baxalta develops, manufactures and markets a diverse portfolio of treatments for hemophilia and other bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute medical conditions. Co. is also investing in new disease areas, including oncology, as well as emerging technology platforms, including gene therapy and biosimilars. Co.'s business consists of a portfolio of products serving patient needs in a variety of ways. Co.'s four groups consist of Hemophilia, Inhibitor Therapies, Immunoglobulin Therapies and BioTherapeutics.

Baxalta SEC Filing Email Alerts Service

Open the BXLT Page at The Online Investor »

Company Name:  Baxalta Inc
Stock buyback:  BXLT buyback
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding BXLT:  76
Total Market Value Held by ETFs:  $760.38M
Total Market Capitalization:  $25.42B
% of Market Cap. Held by ETFs:  2.99%

Open the BXLT Page at The Online Investor (in a new window) »

February 12, 2016    7:17 PM Eastern
Quotes delayed 20 minutes

Buy (2.80 out of 4)
27th percentile
(ranked lower than approx. 73% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | | Copyright © 1998 - 2016, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.